论文部分内容阅读
冠脉内支架置入术目前在临床上广泛应用 ,但内膜增生造成 10 %～ 6 0 % [1] 病人支架内再狭窄 (In StentRestenosis,ISR)。ISR限制了该技术远期的疗效 ,日益成为重要的临床问题。大量实验资料表明西罗莫司 (Sirolimus)能抑制细胞周期 ,减少新生内膜的形成。通过聚合物涂层支架
Coronary stenting is currently widely used clinically, but intimal hyperplasia accounts for 10% to 60% of patients with in-stent restenosis (ISR). ISRs limit the long-term efficacy of this technology and are increasingly important clinical issues. A large number of experimental data show that Sirolimus can inhibit the cell cycle and reduce the formation of neointima. Through a polymer coated stent